{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T06:14:53Z","timestamp":1758608093955,"version":"3.44.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clml.2025.05.010","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:52:33Z","timestamp":1747223553000},"page":"698-704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | The Evolving Landscape of Prognostic Models in Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2795-6507","authenticated-orcid":false,"given":"Stefano","family":"Molica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Allsup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.05.010_bib0001","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.05.010_bib0002","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2025.05.010_bib0003","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hon.2929","article-title":"A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents","volume":"39","author":"Molica","year":"2021","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.05.010_bib0004","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","article-title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.05.010_bib0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Pflug","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.05.010_bib0006","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.05.010_bib0007","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.24660","article-title":"Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI","volume":"92","author":"Delgado","year":"2017","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.clml.2025.05.010_bib0008","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/17474086.2021.1876558","article-title":"Chronic lymphocytic leukemia prognostic models in real life: still a long way off","volume":"14","author":"Molica","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"10.1016\/j.clml.2025.05.010_bib0009","article-title":"Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis","volume":"7","author":"Kreuzberger","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.clml.2025.05.010_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"issue":"8","key":"10.1016\/j.clml.2025.05.010_bib0011","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","article-title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2025.05.010_bib0012","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.2023022564","article-title":"Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies","volume":"143","author":"Langerbeins","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.05.010_bib0013","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/blood-2024-206576","article-title":"Complex karyotype, but not isolated TP53 mutation, predicts overall survival in chronic lymphocytic leukemia patients in the era of targeted therapy","volume":"144","author":"Azevedo","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.05.010_bib0014","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1016\/S2352-3026(19)30085-7","article-title":"Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations","volume":"6","author":"Soumerai","year":"2019","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.05.010_bib0015","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.20.00979","article-title":"Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model","volume":"39","author":"Ahn","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.05.010_bib0016","doi-asserted-by":"crossref","first-page":"E176","DOI":"10.1002\/ajh.26502","article-title":"Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: validation of current prognostic models and development of a simplified three-factor model","volume":"97","author":"Molica","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.05.010_bib0017","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/hematology.2024000571","article-title":"The evolving frontline management of CLL: are triplets better than doublets? How will we find out?","volume":"2024","author":"Rogers","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"10.1016\/j.clml.2025.05.010_bib0018","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/ajh.24493","article-title":"The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: independent validation in a prospective cohort of early stage patients","volume":"91","author":"Molica","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.05.010_bib0019","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood-2017-09-806034","article-title":"Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis","volume":"131","author":"Molica","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.05.010_bib0020","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood.2020009813","article-title":"The CLL-International Prognostic Index (CLL-IPI) predicts outcomes in monoclonal B-cell lymphocytosis and rai 0 CLL","volume":"138","author":"Parikh","year":"2021","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2025.05.010_bib0021","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2019003453","article-title":"International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia","volume":"135","author":"Condoluci","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.05.010_bib0022","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO clinical practice guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.05.010_bib0023","unstructured":"NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) version 1.2025 \u2014 October 1, 2024 chronic lymphocytic leukemia\/small lymphocytic lymphoma. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf. Accessed April 30, 2025."},{"issue":"2","key":"10.1016\/j.clml.2025.05.010_bib0024","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.2021010845","article-title":"The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia","volume":"139","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2025.05.010_bib0025","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1182\/bloodadvances.2023012382","article-title":"It is feasible and safe to stop specialized follow-up of asymptomatic lower risk chronic lymphocytic leukemia","volume":"8","author":"Brieghel","year":"2024","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2025.05.010_bib0026","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/17474086.2024.2366534","article-title":"Defining treatment success in chronic lymphocytic leukemia: exploring surrogate markers, comorbidities, and patient-centered endpoints","volume":"17","author":"Molica","year":"2024","journal-title":"Exp Rev Hematol"},{"issue":"9","key":"10.1016\/j.clml.2025.05.010_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107591","article-title":"A personalized stepwise dynamic predictive algorithm of the time to first treatment in chronic lymphocytic leukemia","volume":"26","author":"Moysiadis","year":"2023","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.clml.2025.05.010_bib0028","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","article-title":"Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction","volume":"178","author":"Kurtz","year":"2019","journal-title":"Cell"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2025.05.010_bib0029","article-title":"et al. a continuous individualized risk index for refined outcome prediction after targeted therapy for patients with chronic lymphocytic leukemia (CIRI-CLL)","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2025.05.010_bib0030","first-page":"96","article-title":"Investigating AI approaches for survival prediction in chronic lymphocytic leukemia","volume":"323","author":"Mouazer","year":"2025","journal-title":"Stud Health Technol Inform"},{"issue":"1","key":"10.1016\/j.clml.2025.05.010_bib0031","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41467-019-14225-8","article-title":"Machine learning can identify newly diagnosed patients with CLL at high risk of infection","volume":"11","author":"Agius","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.clml.2025.05.010_bib0032","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.3390\/curroncol30020148","article-title":"Prediction of clinical outcomes with explainable artificial intelligence in patients with chronic lymphocytic leukemia","volume":"30","author":"Hoffmann","year":"2023","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.05.010_bib0033","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/10428194.2023.2299737","article-title":"Identifying CLL patients at high risk of atrial fibrillation on treatment using machine learning","volume":"65","author":"Parviz","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.05.010_bib0034","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428190701724785","article-title":"Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia","volume":"49","author":"Thurmes","year":"2008","journal-title":"Leuk Lymph"},{"issue":"7 suppl","key":"10.1016\/j.clml.2025.05.010_bib0035","first-page":"1","article-title":"Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death","volume":"35","author":"Rotbain","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2025.05.010_bib0036","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bjh.15784","article-title":"Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies","volume":"186","author":"Burger","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.05.010_bib0037","unstructured":"Frustaci AM, Biagi A, Chiarenza A, et al. Role of age, fitness and concomitant medications in CLL patients treated with venetoclax. The 62nd ASH Annual Meeting and Exposition; (Virtual Meeting), December 5-8, 2020. Abstract 1319."},{"key":"10.1016\/j.clml.2025.05.010_bib0038","doi-asserted-by":"crossref","unstructured":"Baumann T, Delgado J, Santacruz R, et al. Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model. Haematologica;99(10):1599-604.","DOI":"10.3324\/haematol.2014.107326"},{"issue":"26","key":"10.1016\/j.clml.2025.05.010_bib0039","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2017-03-772285","article-title":"CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI","volume":"129","author":"Rigolin","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.05.010_bib0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1053\/j.seminhematol.2024.02.002","article-title":"Prognostication in chronic lymphocytic leukemia","volume":"61","author":"Moia","year":"2024","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.05.010_bib0041","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/asheducation-2018.1.256","article-title":"Richter transformation in the era of novel agents","volume":"2018","author":"Ding","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2025.05.010_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023566","article-title":"Risk factors associated with Richter's transformation in patients with chronic lymphocytic leukaemia: protocol for a retrospective population- based cohort study","volume":"9","author":"Hleuhel","year":"2019","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.clml.2025.05.010_bib0043","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1080\/10428190400029965","article-title":"A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia","volume":"46","author":"Molica","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.clml.2025.05.010_bib0044","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/blood-2005-12-051458","article-title":"Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia","volume":"109","author":"Wierda","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.05.010_bib0045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cncr.24004","article-title":"Validation of a new prognostic index for patients with chronic lymphocytic leukemia","volume":"115","author":"Shanafelt","year":"2009","journal-title":"Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:07:28Z","timestamp":1758604048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2152265025001727"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | The Evolving Landscape of Prognostic Models in Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}